cediranib + lomustine

Cediranib + lomustine is a combination therapy investigated for the treatment of recurrent glioblastoma. Cediranib is an oral small molecule inhibitor targeting vascular endothelial growth factor (VEGF) receptors, thereby inhibiting angiogenesis in tumors. Lomustine is an oral alkylating agent from the nitrosourea class that induces DNA cross-linking and damage, leading to cell death. The combination was evaluated in phase III clinical trials to determine if it improved progression-free survival compared to standard therapy with lomustine alone. While the combination showed some secondary benefits such as delayed neurologic deterioration and corticosteroid-sparing effects, it did not significantly improve progression-free or overall survival compared to monotherapy with lomustine[1][3][6].

Brand names

Recentin + lomustineCeeNu (for lomustine)

Other names

cediranib maleate + lomustinecediranib hydrochloride + lomustine